Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: ahhaha who wrote (177)	2/5/1998 9:49:00 PM
From: John Metcalf	Read Replies (1) \| Respond to of 399

<Glaxo is highly regarded. I could never understand why. They make corporate decisions by committee.> Glaxo was trading below $20 at the time of the Affymax acqusition that Miljenko mentioned. Today they are trading in the $60's. The investor who has been compounding 50% per year doesn't care whether their decisions came out of committees or monkeys rotating 96-well plates. Is there an investable biotech corporation anywhere that doesn't operate by committee? To do otherwise would be to exclude input from several critical disciplines. Solo-ing is good in cowboy movies, but not good bio-molecular science.